Skip to main content

TL1A Inhibitor Deal Benchmarks in Gastroenterology

Median Upfront
$745M
Range: $398M - $1.1B
Total Deal Value
$3.8B
Range: $2.4B - $5.2B
Royalty Rate
8.5% - 15.8%
Tiered up to 19.8%
Dev Milestones
$641M
Range: $419M - $865M
Model Your Deal

Market Analysis

TL1A Inhibitor therapies in gastroenterology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 tl1a inhibitor asset in gastroenterology is $745M, with total deal values reaching $3.8B. Development milestones average $641M, while regulatory milestones contribute $763M.

The gastroenterology tl1a inhibitor landscape is characterized by moderate-to-high competitive intensity concentrated in IBD and eosinophilic GI disorders. TL1A inhibitors, gut-selective integrins, and S1P modulators are broadening the therapeutic toolkit beyond TNF and integrin blockade. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for tl1a inhibitor gastroenterology deals range from 8.5% to 15.8% at the base tier, with tiered escalation reaching 12.5%-19.8% on blockbuster sales. Commercial milestones averaging $1.6B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a tl1a inhibitor gastroenterology licensing deal?
Based on our analysis, Phase 2 tl1a inhibitor licensing deals in gastroenterology average $745M in upfront payments, with a range of $398M to $1.1B depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for tl1a inhibitor gastroenterology transactions?
The median total deal value for Phase 2 tl1a inhibitor assets in gastroenterology is $3.8B, ranging from $2.4B to $5.2B. This includes development milestones ($641M), regulatory milestones ($763M), and commercial milestones ($1.6B).
What royalty rates are standard for tl1a inhibitor deals in gastroenterology?
Base royalty rates for tl1a inhibitor gastroenterology transactions range from 8.5% to 15.8%, with tiered escalations reaching 12.5%-19.8% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in tl1a inhibitor gastroenterology deals?
TL1A Inhibitor gastroenterology deals allocate approximately 80% of total deal value to milestones. Development milestones ($641M) make up the largest share, followed by commercial milestones ($1.6B) and regulatory milestones ($763M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Gastroenterology

View

Monoclonal Antibody in Gastroenterology

View

TL1A Inhibitor in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included